Docetaxel/trastuzumab regime: Uses in HER2-positive early breast cancer

被引：0
|
作者：
Arnheim, Katharina
机构：
来源：
BREAST CARE | 2006年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：A1 / A4
页数：4
相关论文
共 50 条
  • [41] Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
    Tian, Tian
    Ye, Jing
    Zhou, Sihai
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 720 - 727
  • [42] Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).
    Ntekim, Atara Isaiah
    Adeniji-Sofoluwe, Omoba Temitayo
    Sowunmi, Anthonia
    Folasire, Ayorinde
    Olasehinde, Olalekan
    Lawaal, AbdulRazzak
    Olajide, Thomas
    Omodele, Foluso
    Fatiregun, Omolara A.
    Sanni, Ayodele
    Ajani, Mustapha
    Kotila, Olayinka
    Komolafe, Akinwunmi O.
    Ao, Alabi
    Olaniyi, Popoola Abiodun
    Asuzu, Chioma Christie
    Daramola, Adetola
    Babalola, Chinedum Peace
    Karrison, Theodore
    Olopade, Olufunmilayo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [44] Predictors of response to primary systemic therapy (PST) with docetaxel and trastuzumab in HER2-positive breast cancer
    Rao, M.
    Griggs, J. J.
    Schiffhauer, L. M.
    Messina, P.
    Bourne, P.
    Ahrendt, G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Docetaxel, carboplatin and weekly trastuzumab are active as neoadjuvant therapy in operable HER2-positive breast cancer
    Kolberg, H. -C.
    Akpolat-Basci, L.
    Otterbach, F.
    Drumm, A.
    Tirier, C.
    BREAST, 2011, 20 : S74 - S74
  • [46] Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
    Harris, Lyndsay N.
    You, Fanglei
    Schnitt, Stuart J.
    Witkiewicz, Agnes
    Lu, Xin
    Sgroi, Dennis
    Ryan, Paula D.
    Come, Steven E.
    Burstein, Harold J.
    Lesnikoski, Beth-Ann
    Kamma, Madhavi
    Friedman, Paula N.
    Gelman, Rebecca
    Iglehart, J. Dirk
    Winer, Eric P.
    CLINICAL CANCER RESEARCH, 2007, 13 (04) : 1198 - 1207
  • [47] CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN
    Ciruelos, E.
    Alba, E.
    Lopez, R.
    Lluch, A.
    Martin, M.
    Arroyo, I
    Navarro, B.
    Carcedo, D.
    Colomer, R.
    Albanell, J.
    VALUE IN HEALTH, 2018, 21 : S18 - S18
  • [48] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [49] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
  • [50] Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study
    Koudsi, L.
    Hockaday, C.
    Levitt, N.
    Tuthill, M.
    Roux, R.
    Lord, S.
    Chiramel, J.
    CLINICAL ONCOLOGY, 2025, 38
12345